Open an account

Amgen

AMGN · NASDAQ

$438.94+$14.00 (+3.29%)TodayMarket closed ·
Prev close $424.94

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Employees
31,500
Headquarters
Thousand Oaks, California
Listed
Jun 17, 1983
Sector
Health Care
Industry
Biotechnology
Website
amgen.com

AMGN key statistics

Market cap
229.74B
Price-earnings ratio
26.39
Dividend yield
2.23%
Average volume
2.82M
Volume
1.52M
Open price
$425.58
High today
$439.05
Low today
$425.11
52 Week high
$447.03
52 Week low
$288.00

Amgen (AMGN) at a glance

Amgen (AMGN) last traded at $438.94, with a market cap of 229.74B, a price-to-earnings ratio of 26.39 and a dividend yield of 2.23%.

Today the stock has traded between $425.11 and $439.05. The current price is 3.3% above the day's low and 0.0% below its high.

Volume so far is 1.52M shares, below the average of 2.82M shares a day.

Over the past year Amgen has ranged from $288.00 to $447.03, and now sits 95% of the way up that range.

Amgen met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $6.29 per share against an estimate of $5.73.

The average analyst price target is $400.15, 8.8% below the current price, from 26 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

35%of 26 analyst ratings say Buy
  • Buy34.6%
  • Hold53.8%
  • Sell11.5%
Price target · 34 analystsAvg $400.15
Low
$227.25
Now
$438.94
High
$525.00

AMGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 8.6% on average.

  1. Q3 FY24: reported $5.58 per share against an estimate of $5.22
  2. Q4 FY24: reported $5.31 per share against an estimate of $5.18
  3. Q1 FY25: reported $4.90 per share against an estimate of $4.39
  4. Q2 FY25: reported $6.02 per share against an estimate of $5.39
  5. Q3 FY25: reported $5.64 per share against an estimate of $5.11
  6. Q4 FY25: reported $5.29 per share against an estimate of $4.83
  7. Q1 FY26: reported $5.15 per share against an estimate of $4.85
  8. Q2 FY26: reported $6.29 per share against an estimate of $5.73

AMGN news

  • Press releasePRNewswire

    AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

  • Vandana Singh

    AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

  • Press releasePRNewswire

    TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

  • Piero Cingari

    Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

  • Press releasePRNewswire

    KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Vandana Singh

    Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Similar companies

Companies in the same industry as Amgen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.